- authorisedTherapeutic confirmatory (Phase III)
Immunogenicity after a prime dose and revaccination with adjuvanted RSVPreF3 vaccine in the most elderly and frail population – an open-labeled phase IIIb-trial RSV Immunogenicity Study in the Elderly (RISE)
This study, called RISE, looks at how well the Arexvy vaccine works in older adults to protect against RSV, a common chest infection. We're checking how the body's defence system responds to the vaccine in people aged 60-65 and those aged 80 and over.
Sweden - recruiting
Prevention Strategy for Respiratory Syncytial Virus (RSV) Infections in Infants in France
This study in France looks at how pregnant women choose to protect their babies from RSV, a common winter bug. They can either get a vaccine themselves or have their baby given a special injection after birth. Researchers want to understand why women pick one option over the other.
France - active not recruiting
RESCEU: Defining the Burden of RSV Disease
This study, called RESCEU, is looking at how RSV affects healthy babies in the UK. Researchers will follow babies for several years to understand how often they get RSV, how severe it is, and the costs involved. This will help improve care for babies with RSV.
United Kingdom